November 17, 2020

Lumicell Granted Fast Track Designation Approval by the FDA for Breast Cancer Treatment

Lumicell, Inc., an innovation leader in image guided cancer surgery, recently announced it received Fast Track designation with rolling review from the FDA Center for Drug Evaluation and Research (CDER) to expedite the development and review of the LUM Imaging System in the treatment of Breast Cancer. Fast Track designation represents another major milestone in Lumicell’s path to FDA approval.

Lumicell is a previous MLSC awardee through the Center’s Accelerator Loan program. Accelerator loans bridge the gap in a company’s capital-raising lifecycle, providing the company with time and resources to advance to a point at which it would become a good candidate for private investment. Applicants were early-stage life sciences companies with a high potential for technology commercialization, rapid growth, and private equity financing.